U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Myelofibrosis(MMM)

MedGen UID:
10146
Concept ID:
C0026987
Neoplastic Process
Synonyms: MMM; MYELOFIBROSIS; MYELOFIBROSIS WITH MYELOID METAPLASIA
SNOMED CT: MF - Myelofibrosis (52967002); Myelosclerosis (52967002); Myelofibrosis (52967002)
 
HPO: HP:0011974
Monarch Initiative: MONDO:0044903
OMIM®: 254450

Definition

Replacement of bone marrow by fibrous tissue. [from HPO]

Conditions with this feature

Primary myelofibrosis
MedGen UID:
7929
Concept ID:
C0001815
Neoplastic Process
Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.\n\nInitially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.\n\nBecause blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain.\n\nPrimary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.
Gray platelet syndrome
MedGen UID:
82900
Concept ID:
C0272302
Disease or Syndrome
The gray platelet syndrome (GPS) is a rare inherited disorder characterized by mild to moderate bleeding tendency, moderate thrombocytopenia, and a marked decrease or absence of platelet alpha-granules and of the proteins contained in alpha-granules. The platelets are enlarged, but not giant, and have a gray appearance on light microscopy of Wright-stained peripheral blood smears due to decreased granules. Many patients with gray platelet syndrome develop a stable myelofibrosis (summary by Nurden and Nurden, 2007). Cases suggesting autosomal dominant and autosomal recessive inheritance have been described, indicating that GPS is probably a genetically heterogeneous disorder with more than one molecular cause.
Ghosal hematodiaphyseal dysplasia
MedGen UID:
344739
Concept ID:
C1856465
Congenital Abnormality
Ghosal hematodiaphyseal dysplasia (GHDD) is an autosomal recessive disorder characterized by increased bone density with predominant diaphyseal involvement and aregenerative corticosteroid-sensitive anemia (summary by Genevieve et al., 2008).
Platelet-type bleeding disorder 17
MedGen UID:
396078
Concept ID:
C1861194
Disease or Syndrome
Platelet-type bleeding disorder-17 is an autosomal dominant disorder characterized by increased bleeding tendency due to abnormal platelet function. It is a type of 'gray platelet syndrome' because the platelets appear abnormal on light microscopy. Electron microscopy shows decreased or absent alpha-granules within platelets, and bone marrow biopsy shows increased numbers of abnormal megakaryocytes, suggesting a defect in megakaryopoiesis and platelet production. The bleeding severity is variable (summary by Monteferrario et al., 2014).
14q32 duplication syndrome
MedGen UID:
896239
Concept ID:
C4225449
Disease or Syndrome
A rare chromosomal anomaly syndrome resulting from the partial duplication of the long arm of chromosome 14 that results in a predisposition to a number of adult-onset myeloproliferative neoplasms, including acute myeloid leukaemia, chronic myelomonocytic leukaemia and myeloproliferative neoplasms especially essential thrombocythemia. Progression to myelofibrosis and secondary acute myeloid leukaemia can be observed.
Thrombocytopenia 6
MedGen UID:
934756
Concept ID:
C4310789
Disease or Syndrome
Thrombocytopenia-6 is an autosomal dominant hematologic disorder characterized by increased bleeding episodes due to reduced platelet count and abnormal platelet morphology resulting from defective megakaryopoiesis. Patients may also have bone abnormalities, including osteoporosis or tooth loss, as well as an increased risk for myelofibrosis (summary by Turro et al., 2016). For a general phenotypic description and a discussion of genetic heterogeneity of thrombocytopenia, see 313900.
Noonan syndrome-like disorder with loose anagen hair 1
MedGen UID:
1379805
Concept ID:
C4478716
Disease or Syndrome
Noonan syndrome-like disorder with loose anagen hair is characterized by facial features similar to those observed in Noonan syndrome (163950), including hypertelorism, ptosis, downslanting palpebral fissures, low-set posteriorly angulated ears, and overfolded pinnae. In addition, patients display short stature, frequently with growth hormone (GH; see 139250) deficiency; cognitive deficits; relative macrocephaly; small posterior fossa resulting in Chiari I malformation; hypernasal voice; cardiac defects, especially dysplasia of the mitral valve and septal defects; and ectodermal abnormalities, in which the most characteristic feature is the hair anomaly, including easily pluckable, sparse, thin, slow-growing hair (summary by Bertola et al., 2017). Reviews Komatsuzaki et al. (2010) reviewed the clinical manifestations of patients with Noonan syndrome, Costello syndrome (218040), and cardiofaciocutaneous syndrome (CFC; see 115150) compared to patients with mutations in the SHOC2 gene. They noted that although there is phenotypic overlap among the disorders, loose anagen/easily pluckable hair had not been reported in mutation-positive patients with Noonan, CFC, or Costello syndrome, and appeared to be a distinctive feature of SHOC2 mutation-positive patients. Genetic Heterogeneity of Noonan Syndrome-Like Disorder with Loose Anagen Hair NSLH2 (617506) is caused by mutation in the PPP1CB gene (600590) on chromosome 2p23.
Thrombocytopenia, anemia, and myelofibrosis
MedGen UID:
1378448
Concept ID:
C4479504
Disease or Syndrome
Immunodeficiency 98 with autoinflammation, X-linked
MedGen UID:
1805285
Concept ID:
C5676883
Disease or Syndrome
X-linked immunodeficiency-98 with autoinflammation (IMD98) is characterized by onset of recurrent infections associated with lymphoproliferation and autoinflammation in the first decade of life. Mostly males are affected; carrier females may have mild symptoms. Laboratory studies show evidence of immune dysregulation, including hypogammaglobulinemia with reduced memory B cells, skewed T-cell subsets, increased levels of proinflammatory cytokines, activated T cells and monocytes, and autoimmune cytopenias, including neutropenia (Aluri et al., 2021; Fejtkova et al., 2022).

Professional guidelines

PubMed

Tefferi A, Vannucchi AM, Barbui T
Am J Hematol 2024 Apr;99(4):697-718. Epub 2024 Jan 25 doi: 10.1002/ajh.27216. PMID: 38269572
Tefferi A, Barbui T
Am J Hematol 2023 Sep;98(9):1465-1487. Epub 2023 Jun 26 doi: 10.1002/ajh.27002. PMID: 37357958
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Myeloproliferative Neoplasms, 2023

Recent clinical studies

Etiology

Kröger N, Wolschke C, Gagelmann N
Blood 2023 Nov 16;142(20):1683-1696. doi: 10.1182/blood.2023021218. PMID: 37647853
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
Garmezy B, Schaefer JK, Mercer J, Talpaz M
Blood Rev 2021 Jan;45:100691. Epub 2020 Apr 7 doi: 10.1016/j.blre.2020.100691. PMID: 32354563
Harrison CN, Schaap N, Mesa RA
Ann Hematol 2020 Jun;99(6):1177-1191. Epub 2020 Mar 20 doi: 10.1007/s00277-020-04002-9. PMID: 32198525Free PMC Article
Gangat N, Tefferi A
Br J Haematol 2020 Oct;191(2):152-170. Epub 2020 Mar 20 doi: 10.1111/bjh.16576. PMID: 32196650

Diagnosis

Mahmud M, Vasireddy S, Gowin K, Amaraneni A
Int J Mol Sci 2023 Dec 12;24(24) doi: 10.3390/ijms242417383. PMID: 38139212Free PMC Article
Ng ZY, Fuller KA, Mazza-Parton A, Erber WN
Int J Lab Hematol 2023 Jun;45 Suppl 2:59-70. Epub 2023 May 21 doi: 10.1111/ijlh.14086. PMID: 37211431
El-Sharkawy F, Margolskee E
Clin Lab Med 2021 Sep;41(3):529-540. doi: 10.1016/j.cll.2021.04.010. PMID: 34304780
Garmezy B, Schaefer JK, Mercer J, Talpaz M
Blood Rev 2021 Jan;45:100691. Epub 2020 Apr 7 doi: 10.1016/j.blre.2020.100691. PMID: 32354563
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socié G, Beelen D, Triviai I, Badbaran A, Kröger N
Blood 2019 May 16;133(20):2233-2242. Epub 2019 Feb 13 doi: 10.1182/blood-2018-12-890889. PMID: 30760453

Therapy

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators
Lancet 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. PMID: 36709073
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Harrison CN, Schaap N, Mesa RA
Ann Hematol 2020 Jun;99(6):1177-1191. Epub 2020 Mar 20 doi: 10.1007/s00277-020-04002-9. PMID: 32198525Free PMC Article
Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB
Haematologica 2019 Jun;104(6):1112-1123. Epub 2019 May 9 doi: 10.3324/haematol.2018.212845. PMID: 31073079Free PMC Article
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J
J Clin Oncol 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20 doi: 10.1200/JCO.2017.73.4418. PMID: 28930494Free PMC Article

Prognosis

Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM
Leukemia 2017 Dec;31(12):2726-2731. Epub 2017 May 31 doi: 10.1038/leu.2017.169. PMID: 28561069
Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators
J Hematol Oncol 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z. PMID: 28228106Free PMC Article
Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA
Eur J Haematol 2014 Apr;92(4):289-97. Epub 2014 Feb 3 doi: 10.1111/ejh.12256. PMID: 24372927
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G
N Engl J Med 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556. PMID: 22375970

Clinical prediction guides

Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Passamonti F, Mora B
Blood 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. PMID: 36416738Free PMC Article
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
Gangat N, Tefferi A
Br J Haematol 2020 Oct;191(2):152-170. Epub 2020 Mar 20 doi: 10.1111/bjh.16576. PMID: 32196650
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J
J Clin Oncol 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20 doi: 10.1200/JCO.2017.73.4418. PMID: 28930494Free PMC Article

Recent systematic reviews

Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ
Clin Pharmacokinet 2023 Apr;62(4):559-571. Epub 2023 Mar 31 doi: 10.1007/s40262-023-01225-7. PMID: 37000342Free PMC Article
Nurgat Z, Lawrence M
J Oncol Pharm Pract 2022 Sep;28(6):1400-1410. Epub 2022 Mar 16 doi: 10.1177/10781552221082293. PMID: 35296179
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M
Clin Lymphoma Myeloma Leuk 2020 Oct;20(10):e712-e723. Epub 2020 May 28 doi: 10.1016/j.clml.2020.05.018. PMID: 32669244Free PMC Article
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE
Cancer Treat Rev 2017 Feb;53:47-52. Epub 2016 Dec 22 doi: 10.1016/j.ctrv.2016.11.016. PMID: 28063304Free PMC Article
Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS
Semin Ultrasound CT MR 2014 Jun;35(3):255-62. Epub 2013 Dec 19 doi: 10.1053/j.sult.2013.12.001. PMID: 24929265

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2023
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Myeloproliferative Neoplasms, 2023

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...